Philip Wenzel1, Heidi Rossmann2, Christian Müller3, Sabine Kossmann4, Matthias Oelze5, Andreas Schulz5, Natalie Arnold5, Canan Simsek5, Jeremy Lagrange6, Roman Klemz7, Tanja Schönfelder6, Moritz Brandt5, Susanne H Karbach5, Maike Knorr5, Stefanie Finger6, Carolin Neukirch2, Friederike Häuser2, Manfred E Beutel8, Swenja Kröller-Schön5, Eberhard Schulz5, Renate B Schnabel3, Karl Lackner2, Philipp S Wild9, Tanja Zeller3, Andreas Daiber5, Stefan Blankenberg3, Thomas Münzel10. 1. Department of Medicine 2, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany German Center for Cardiovascular Research (DZHK), Partner Site RhineMain, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany wenzelp@uni-mainz.de. 2. Department of Laboratory Medicine, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany. 3. University Heart Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Luebeck, Germany. 4. Department of Medicine 2, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany. 5. Department of Medicine 2, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany. 6. Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany. 7. Laboratory of Chronobiology, Charité University Medical Center Berlin, Hessische Str. 3-4, 10115 Berlin, Germany. 8. Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany. 9. Department of Medicine 2, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany German Center for Cardiovascular Research (DZHK), Partner Site RhineMain, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany. 10. Department of Medicine 2, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany German Center for Cardiovascular Research (DZHK), Partner Site RhineMain, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany.
Abstract
AIMS: Heme oxygenase-1 (HO-1) confers protection to the vasculature and suppresses inflammatory properties of monocytes and macrophages. It is unclear how HO-1 determines the extent of vascular dysfunction in mice and humans. METHODS AND RESULTS: Decreased HO-1 activity and expression was paralleled by increased aortic expression and activity of the nicotinamide dinucleotide phosphate oxidase Nox2 in HO-1 deficient Hmox1⁻/⁻ and Hmox1(⁺/⁻) compared with Hmox1⁺/⁺ mice. When subjected to angiotensin II-infusion, streptozotocin-induced diabetes mellitus and aging, HO-1 deficient mice showed increased vascular dysfunction inversely correlated with HO activity. In a primary prevention population-based cohort, we assessed length polymorphisms of the HMOX1 promoter region and established a bipolar frequency pattern of allele length (long vs. short repeats) in 4937 individuals. Monocytic HMOX1 mRNA expression was positively correlated with flow-mediated dilation and inversely with CD14 mRNA expression indicating pro-inflammatory monocytes in 733 hypertensive individuals of this cohort. Hmox1⁻/⁻ mice showed drastically increased expression of the chemokine receptor CCR2 in monocytes and the aorta. Angiotensin II-infused Hmox1⁻/⁻ mice had amplified endothelial inflammation in vivo, significantly increased aortic infiltration of pro-inflammatory CD11b⁺ Ly6C(hi) monocytes and Ly6G⁺ neutrophils and were marked by Ly6C(hi) monocytosis in the circulation and an increased blood pressure response. Finally, individuals with unfavourable HMOX1 gene promoter length had increased prevalence of arterial hypertension and reduced cumulative survival after a median follow-up of 7.23 years. CONCLUSIONS: Heme oxygenase-1 is a regulator of vascular function in hypertension via determining the phenotype of inflammatory circulating and infiltrating monocytes with possible implications for all-cause mortality. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Heme oxygenase-1 (HO-1) confers protection to the vasculature and suppresses inflammatory properties of monocytes and macrophages. It is unclear how HO-1 determines the extent of vascular dysfunction in mice and humans. METHODS AND RESULTS: Decreased HO-1 activity and expression was paralleled by increased aortic expression and activity of the nicotinamide dinucleotide phosphate oxidase Nox2 in HO-1 deficient Hmox1⁻/⁻ and Hmox1(⁺/⁻) compared with Hmox1⁺/⁺ mice. When subjected to angiotensin II-infusion, streptozotocin-induced diabetes mellitus and aging, HO-1 deficient mice showed increased vascular dysfunction inversely correlated with HO activity. In a primary prevention population-based cohort, we assessed length polymorphisms of the HMOX1 promoter region and established a bipolar frequency pattern of allele length (long vs. short repeats) in 4937 individuals. Monocytic HMOX1 mRNA expression was positively correlated with flow-mediated dilation and inversely with CD14 mRNA expression indicating pro-inflammatory monocytes in 733 hypertensive individuals of this cohort. Hmox1⁻/⁻ mice showed drastically increased expression of the chemokine receptor CCR2 in monocytes and the aorta. Angiotensin II-infused Hmox1⁻/⁻ mice had amplified endothelial inflammation in vivo, significantly increased aortic infiltration of pro-inflammatory CD11b⁺ Ly6C(hi) monocytes and Ly6G⁺ neutrophils and were marked by Ly6C(hi) monocytosis in the circulation and an increased blood pressure response. Finally, individuals with unfavourable HMOX1 gene promoter length had increased prevalence of arterial hypertension and reduced cumulative survival after a median follow-up of 7.23 years. CONCLUSIONS:Heme oxygenase-1 is a regulator of vascular function in hypertension via determining the phenotype of inflammatory circulating and infiltrating monocytes with possible implications for all-cause mortality. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Cheng Wang; Zaiming Luo; Gabriella Carter; Anton Wellstein; Pedro A Jose; James Tomlinson; James Leiper; William J Welch; Christopher S Wilcox; Dan Wang Journal: Am J Physiol Regul Integr Comp Physiol Date: 2017-11-22 Impact factor: 3.619
Authors: Lukas Andreas Heger; Mark Kerber; Marcus Hortmann; Samuel Robinson; Maximilian Mauler; Daniela Stallmann; Daniel Duerschmied; Christoph Bode; Christoph Hehrlein; Ingo Ahrens Journal: Acta Pharmacol Sin Date: 2018-07-10 Impact factor: 6.150
Authors: Susanne H Karbach; Tanja Schönfelder; Ines Brandão; Eivor Wilms; Nives Hörmann; Sven Jäckel; Rebecca Schüler; Stefanie Finger; Maike Knorr; Jeremy Lagrange; Moritz Brandt; Ari Waisman; Sabine Kossmann; Katrin Schäfer; Thomas Münzel; Christoph Reinhardt; Philip Wenzel Journal: J Am Heart Assoc Date: 2016-08-30 Impact factor: 5.501